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Abstract
Extensive antibiotic use over the years has led to the emergence and spread of antibiotic
resistant bacteria (ARB). Antibiotic resistance poses a major threat to public health since for
many infections antibiotic treatment is no longer effective. Hospitals are focal points for ARB
spread. Antibiotic use in hospitals exerts selective pressure, accelerating the spread of
ARB. We used an agent-based model to explore the impact of antibiotics on the transmis-
sion dynamics and to examine the potential of stewardship interventions in limiting ARB
spread in a hospital. Agents in the model consist of patients and health care workers
(HCW). The transmission of ARB occurs through contacts between patients and HCW and
between adjacent patients. In the model, antibiotic use affects the risk of transmission by
increasing the vulnerability of susceptible patients and the contagiousness of colonized
patients who are treated with antibiotics. The model shows that increasing the proportion of
patients receiving antibiotics increases the rate of acquisition non-linearly. The effect of anti-
biotics on the spread of resistance depends on characteristics of the antibiotic agent and the
density of antibiotic use. Antibiotic’s impact on the spread increases when the bacterial
strain is more transmissible, and decreases as resistance prevalence rises. The individual
risk for acquiring ARB increases in parallel with antibiotic density both for patients treated
and not treated with antibiotics. Antibiotic treatment in the hospital setting plays an important
role in determining the spread of resistance. Interventions to limit antibiotic use have the
potential to reduce the spread of resistance, mainly by choosing an agent with a favorable
profile in terms of its impact on patient’s vulnerability and contagiousness. Methods to mea-
sure these impacts of antibiotics should be developed, standardized, and incorporated into
drug development programs and approval packages.
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Introduction
Antibiotics have drastically reduced deaths and complications caused by bacterial infections
and set the stage for modern medicine [1, 2]. However, the wide use of antibiotics has a price.
Antibiotic use promotes the emergence and spread of resistant strains, leading to the exhaus-
tion of this limited resource. After 70 years of excessive antibiotic use by humans, the World
Health Organization warns that the increase in antibiotic-resistant bacteria (ARB) "threatens
the achievements of modern medicine" [3]. Some predict that soon antibiotic resistance will
lead to more deaths than cancer [4]. Humans can acquire ARB in two ways: occasionally, by de
novo emergence of a mechanism of resistance in an individual patient, or, much more com-
monly, by transmission of bacteria that are already resistant. Some resistance mechanisms
(e.g., VanA, CTX-M extended-spectrum beta-lactamases, KPC and NDM carbapenamases)
arose in human pathogens only in a few instances during evolution, but have become wide-
spread through transmission [5, 6]. Highly transmissible successful bacterial clones (such as E.
faecium CC 17, E. coli ST131 or K. pneumoniae clonal group 258) that carry these mechanisms
of resistance often drives their wide dissemination. Thus, it is transmission that turns rare
events into a major public health problem [7].
For many ARB hospitals are the focal points for spread, with transmission occurring from
patient to patient via contact with contaminated healthcare workers (HCW), other patients, or
objects. The transmission dynamics of ARB in hospitals is therefore influenced by the interac-
tions of patients and HCW and their specific characteristics and behavior [8–10]. In hospitals,
transmission of ARB is accelerated by antibiotic pressure [11–13]. Several observational or
quasi-experimental studies of interventions to reduce the use of certain types of antibiotics in
hospitals reported a subsequent decline in ARB [14–16]; one modeling study found that limit-
ing antibiotic use could decrease or increase ARB, depending on the antibiotic class [17].
Antibiotic treatment may facilitate the transmission of ARB in two ways. First, antibiotics
disrupt the commensal flora that protect against colonization by invading bacteria, increasing
patients’ vulnerability to acquire new strains [18]. Thus, patients who are exposed to ARB dur-
ing or shortly after antibiotic treatment are at a higher risk of becoming colonized [19–21].
Studies have reported a 2-9-fold increased risk of ARB acquisition among patients treated with
various antibiotics; this increased risk differs between antibiotic agents [22–24]. Second, in
patients who are already colonized by ARB, antibiotics eradicate competing commensal organ-
isms that are antibiotic-sensitive, allowing overgrowth of those that are resistant. The increased
load of ARB leads to enhanced shedding and thus to greater contagiousness [19, 23]. Studies
have measured a 3.5–5.3 fold greater risk for ARB contamination in the immediate surround-
ings of colonized patients who received antibiotics, and have linked antibiotic use with colo-
nized patients who were heavy dispersers [24, 25]. Furthermore, colonized patients not treated
with antibiotics were found to have an 80% lower risk of room contamination [26].
The proportion of patients treated with antibiotics in hospitals varies greatly, between 21%
and 55% according to European reports [27]. Even greater variation (up to 22-fold) is found
when examining specific antibiotic agents used in different wards housing patients with simi-
lar characteristics [28]. This high variability suggests that the use of antibiotics is amendable.
Here, we used an agent-based model (ABM) to investigate the impact of antibiotic treat-
ment on the transmission dynamics of ARB in a hospital, and the potential of antibiotic stew-
ardship interventions in limiting the spread. The ABM enables us to answer questions where
controlled experimentation is complex and may not be feasible [29–31]. We address the overall
effect of antibiotic pressure on the spread of resistance under various conditions of antibiotic
density, antibiotic agents’ characteristics, prevalence level of ARB, and the contagiousness of
the ARB strain.
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Materials and methods
Model overview
The model is implemented in GAMA 1.7 modeling environment [http://gama-platform.org/].
The setting of the model is a typical hospital (Table 1). Agents consist of patients and health
care workers (HCW). Contacts between patients and HCW and between adjacent patients are
explicitly simulated; these contacts may result in transmission of ARB. Patients admitted to the
hospital are assigned to an available bed in one of the wards and their length of stay (LOS) is
determined based on a random draw from a lognormal distribution. A fraction of admitted
patients is already colonized; since ARB carriage is correlated with an extended length of stay,
colonized patients are assigned with LOS from a lognormal distribution with a higher average
[32–34] (Table 1). In addition, acquisition of ARB during hospital stay prolongs the patient’s
stay. In accordance with studies on the average duration of colonization we assume that
patients remain colonized for the whole duration of their stay [34–38]. On admission, a frac-
tion of patients are prescribed antibiotic treatment. We define two types of antibiotic effect on
treated patient: V-type is the increase in the vulnerability of a susceptible patient to acquire
ARB and represents the fold increase in the risk of acquisition; C-type is the increase in the
contagiousness of a colonized patient and represents the fold increase in the risk of the patient
to transmit ARB. The duration of the treatment is assigned for 10 days or until the patient is
discharged (in case patient’s LOS is less than10 days). We consider the prescription of antibiot-
ics as independent of the colonization state of the patient; that is, the antibiotics are prescribed
to treat or prevent infections caused by other pathogens. Ward staff are assigned to specific
patients within a single ward: each ward staff member is responsible for 8 patients within the
ward ("staff cohorting"). General hospital staff members are not affiliated with a single ward;
they can have contact with patients in any of the wards. Each type of HCW is characterized by
a contact frequency with patients and can be transiently contaminated with ARB during a con-
tact with a colonized patient. ARB contamination is cleared if infection control measures such
as hand hygiene are implemented by HCW before or after contact with a patient.




Number of wards 20 40 patients per ward
HCW
Ward staff 5 per ward
General hospital staff 80 Moves across wards
Ward staff contact with patients 4 per hour Assigned to 8 patients
General hospital staff contact with patients 3 per hour
Compliance with standard
infection control
50% of opportunities Hand hygiene opportunities are
before and after contact with a patient
Patients
Average LOS, susceptible 6 days Lognormal distribution
Average LOS, colonized 12 days Lognormal distribution
Extension of LOS after acquiring ARB 50%
Percent colonized on admission 1% or 10%
https://doi.org/10.1371/journal.pone.0197111.t001
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Transmission of ARB and the impact of antibiotic treatment
ARB transmission is defined by three basic probabilities: a) βP—probability of susceptible
patients to acquire ARB during contact with a contaminated HCW; b) βH—probability of
HCW contamination during contact with a colonized patient; c) α- probability per day of sus-
ceptible patients to acquire ARB from an adjacent colonized patient. In the model, antibiotic
use increases the risk of transmission. V and C represent the fold increase in the risk of ARB
acquisition (for susceptible patient) or of transmission (for colonized patient), respectively,
during antibiotic treatment. When antibiotic is not used by the patient then V = 1 and C = 1.
The following equations determine the probability of transmission between agents:
Probability for susceptible patient to acquire ARB (Pp_by_p) from an adjacent colonized
patient, per day:
Pp by p ¼ a  V  C ð1Þ
Probability for susceptible patient to acquire ARB (Pp_by_h) during a contact with a contam-
inated HCW:
Pp by h ¼ bP  V ð2Þ
Probability for HCW to be contaminated (Ph_by_p) during a contact with a colonized
patient:
Ph by p ¼ bH  C ð3Þ
Simulation experiments
Transmission probabilities are based on values estimated in the literature. Since the estimated
values in those studies include the impact of antibiotics (the study population includes a mix
of patients treated and not treated with antibiotics), we selected values slightly lower than what
was found in the literature as the baseline probabilities for patients who are not treated with
antibiotics. (Table 2). Patient-to-patient transmission probability (α) is based on studies that
estimated acquisition risk in patients whose prior room occupant was a carrier of ARB. Using
simulations, we examine the influence of 4 different variables on transmission of ARB:
1. Characteristics of the antibiotic agent: the fold increase in the risk of ARB acquisition (V)
or transmission (C) during antibiotic treatment; these values vary in simulations between 1
and 4. The tested values are within the range of increased risk for acquisition observed
among patients treated with various antibiotics [23–25], and the increased risk for ARB
shedding and contamination of the surroundings by colonized patients who received anti-
biotics [20, 24–26].
2. Antibiotic density: the prevalence of antibiotic use is varied by changing either the propor-
tion of admitted patients which are treated with antibiotics (0–100%) or the duration of
antibiotic treatment (7 or 10 days).
Table 2. Baseline transmission probabilities, by ARB strain.
Transmission probabilities ARB-L ARB-H Values cited in the literature Source
βH−Contamination of a HCW from a colonized patient, per contact 5% 10% 6%-40% [39–44]
βP−Transmission from a contaminated HCW to a susceptible patient, per contact 2.5% 5% 6%-20% [23, 39–41]
α–Transmission from a colonized patient to a susceptible adjacent patient, per day 0.5% 1% 1%-3% [45–47]
https://doi.org/10.1371/journal.pone.0197111.t002
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3. ARB prevalence among admitted patients: an early stage of ARB spread in which 1% of
admitted patients are carriers, and an endemic stage in which 10% are carriers.
4. Transmissibility of the ARB: a less transmissible strain (ARB-L) and a highly transmissible
strain (ARB-H) (Table 2).
For each scenario, the average of 100 simulations is presented as the results.
Results
The effect of antibiotic characteristics
Antibiotic agents may differ in their effects on patients’ vulnerability (V) and contagiousness
(C). The effect of these antibiotic characteristics on the transmission of ARB was examined.
Transmission of ARB-L and ARB-H was simulated for various combinations of V and C. In
these simulations 1% of admitted patients carry the ARB strain and 40% of admitted patients
receive antibiotics.
Under conditions of no antibiotic pressure (C = 1 and V = 1, the antibiotic agent does not
change contagiousness or vulnerability), the acquisition incidence for the ARB-L strain is 20
per 100,000 patient-days (PD) (Fig 1A, right axis, green line at V = 1). When an antibiotic
agent that increases either V or C is used, the acquisition rate increases; a synergistic effect on
the incidence of ARB acquisition is seen when an antibiotic agent that increases both V and C
is used. For example, when an agent that increases both vulnerability and contagiousness of
the treated patient by four folds (V = 4, C = 4) is used, the incidence rate increases by 230%
(from 20 to 66 acquisitions per 100,000 PD) (Fig 1A). For the more transmissible strain
ARB-H, the baseline acquisition incidence with no antibiotic pressure is much higher: 115
acquisitions per 100,000 PD (Fig 1B, right axis, green line at V = 1). When an antibiotic
increases vulnerability and contagiousness by four folds (V = 4, C = 4) is used, the incidence
rate increases by 679% and reaches 896 acquisitions per 100,000 PD (Fig 1B). Thus, antibiotic
Fig 1. Impact of antibiotic characteristics on acquisition of ARB. Increase in incidence of acquisition (left axis) of (A) strain ARB-L and (B) strain
ARB-H relative to no antibiotic impact, and ARB acquisitions per 100,000 patient days (PD) (right axis) for various values of an antibiotic’s impact on
vulnerability (V) of susceptible patients and on contagiousness (C) of colonized patients. In the simulated scenario 40% of admissions receive
antibiotics and 1% of patients are colonized on admission. Note that when V = 1 and C = 1, antibiotics have no effect on acquisition, or, alternatively,
no patients are receiving antibiotics.
https://doi.org/10.1371/journal.pone.0197111.g001
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treatment has a greater impact on transmission when the ARB strain is more transmissible.
Furthermore, as the impact of the antibiotic increases, ARB transmission increases non-line-
arly, approaching exponential increase for a highly transmissible strain.
We can also infer that an antibiotic’s effect on increasing the vulnerability of susceptible
patients has a greater influence on acquisition dynamics than its effect on increasing the con-
tagiousness of colonized patients. Fig 1B depicts this difference in the case of ARB-H. When
using an antibiotic agent that does not increase vulnerability (V = 1) but increases contagious-
ness by 2–4 fold (2 C 4), the acquisition rate relative to no antibiotic effect increases by
23% - 67% (moving vertically from the blue to the red line in Fig 1B). When using an antibiotic
agent that does not increase contagiousness (C = 1) but increases vulnerability by 2–4 fold
(2 V 4), the acquisition rate relative to no antibiotic effect increases by 50% - 230% (green
line in Fig 1B). This is also true, but to a lesser degree, in the case of the less transmissible ARB
strain (Fig 1A).
The impact of antibiotic density on incidence of ARB acquisition
We varied antibiotic density by changing the proportion of admitted patients prescribed anti-
biotics for 10 days, and explored the effect on the incidence of ARB-L and ARB-H acquisition.
In these simulations we modeled an antibiotic that doubles both vulnerability and contagious-
ness (V = 2, C = 2), and an early stage of ARB spread (1% are carriers upon admission). The
simulations demonstrated that an increase in antibiotic density leads to a non-linear increase
in the incidence of ARB acquisition, which approaches exponential increase in the case of
ARB-H (Fig 2). When antibiotic density is high, the slope of ARB acquisition is steeper, indi-
cating that reductions in antibiotic use will have a greater impact on ARB transmission in set-
tings with high antibiotic density. Comparing the two resistant strains shows that the impact
Fig 2. Increase in ARB acquisitions relative to no antibiotic use as antibiotic density increases. The ARB
prevalence on admission is 1%, and antibiotic impact is V = 2, C = 2. With no antibiotic use, the number of ARB
acquisitions per 100,000 patient-days is 20 for ARB-L and 115 for ARB-H. The % increase in incidence (y axis) refers
to these baseline rates.
https://doi.org/10.1371/journal.pone.0197111.g002
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of antibiotic treatment on the transmission rate is greater for ARB-H than for ARB-L. This
suggests that the spread of highly transmissible ARB is much more sensitive to changes in anti-
biotic density, particularly in high antibiotic density conditions.
The impact of antibiotic density on the individual risk for ARB acquisition
To examine the significance of ARB prevalence on transmission dynamics, we modeled an anti-
biotic agent that doubles vulnerability and contagiousness (V = 2, C = 2). We varied antibiotic
density by changing the proportion of admitted patients treated with antibiotics. Simulations
included both early and established stages of ARB spread (1% vs. 10% carriers upon admission).
First, we examined how increasing antibiotic density affects the incidence of acquisition of
ARB-H and ABR-L compared to a baseline transmission with no antibiotic use (Fig 3, solid
line, right axis). In both stages of ARB spread an increase in antibiotic density leads to an
increase in ARB acquisitions. However, in the stage where of ARB spread is established, the
impact of antibiotic density on ARB transmission is lower. For instance, in the early stage of
spread at high antibiotic density (80% of admitted patients are treated) incidence increase by
260% (Fig 3A) compared to 114% in an established stage of the spread (Fig 3B). This elevated
impact in early stage of the spread is more moderate in case of ARB-L (Fig 3C and 3D).
Increasing antibiotic density affects an individual patient’s risk of acquiring ARB. We mea-
sured the risk as the probability of acquisition during a typical hospital stay of 6 days. The
probability of acquisition for a patient not treated with antibiotics is calculated as: the number
of patients not treated with antibiotics who acquired ARB divided by the total number of
patients not treated with antibiotics.
The probability of acquisition for a patient treated with antibiotics is calculated as: the num-
ber of patients treated with antibiotics who acquired ARB divided by the total number of
patients treated with antibiotics. Since the average antibiotic treatment time was 4.5 days, we
adjusted the probability to account for 6 days with antibiotic treatment.
The individual risk increases in parallel to the proportion of patients treated with antibiotics
(Fig 3, bars, left axis). This is true both for patients treated and not treated with antibiotics. In
the scenario of an early stage of spread, the resulting risk to an individual patient of acquiring
ARB-H is 0.85% when no patients receive antibiotics (Fig 3A). When 20% of admitted patients
are treated with antibiotics, the risk for a patient who is treated with antibiotics nearly doubles
to 1.5% (Fig 3B, black bar). The risk increases 4-fold (to 3.4%) when 80% of admitted patients
receive antibiotics, and doubles to 1.95% for patients not treated (Fig 3A). In an established
stage of ARB spread, the risk for a patient treated with antibiotics doubles to 8% when 20% of
patients admitted receive antibiotics, and nearly triples to 11% when 80% of admissions receive
antibiotics. In an established stage of ARB spread, the effect of antibiotic density on the acqui-
sitions is more modest; in an-early stage, increasing antibiotic density from 20% to 40%
increases the risk of acquisition by 40% compared to only 20% in an established stage. Similar
effects on an individual’s risk for acquisition is also evident for ARB-L, but to a lesser degree
(Fig 3C and 3D).
Antibiotic stewardship interventions
Last, we explored the potential effect of antibiotic stewardship interventions recommended
by the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemi-
ology of America (SHEA) in order to limit resistance [48]. We examined interventions that
decrease the number of patients treated with antibiotics, shorten the duration of antibiotic
courses, and replace antibiotic agents with high impact values (V and C) with ones with low
impact. The simulated scenarios included 1% and 10% prevalence of ARB-H colonization on
Transmission of antibiotic resistance
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admission. ARB-H acquisitions following the simulated intervention were compared to a ref-
erence scenario in which 40% of admissions receive antibiotic agent A with pronounced effects
on vulnerability and contagiousness (V = 4, C = 4) for 10 days.
As presented in Fig 4, stewardship interventions can significantly decrease transmission.
The relative impact of the intervention on ARB transmission is higher at an early stage of ARB
spread, when 1% of admitted patients are carriers, than when ARB spread is established and
10% are carriers. In the most comprehensive intervention scenario, when the proportion of
admitted patients who receive antibiotics is reduced from 40% to 20%, the duration of treat-
ment is reduced from 10 to 7 days, and an antibiotic agent with a lower impact is used
Fig 3. Individual risk for ARB acquisition. Probability of ARB-H and ARB-L acquisition during a 6-day hospital stay for patients
treated and not treated with antibiotics (left axis) and the increase in incidence relative to the scenario without antibiotic use (right
axis); (A) 1% of admissions are colonized with ARB-H (B) 10% of admissions are colonized with ARB-H (C) 1% of admissions are
colonized with ARB-L (D) 10% of admissions are colonized with ARB-L. Antibiotic agent impact: V = 2, C = 2.
https://doi.org/10.1371/journal.pone.0197111.g003
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(scenario I), acquisitions decreased by 83% and 59%, depending on the prevalence of coloniza-
tion on admission. In scenario VI, merely shortening the length of treatment from 10 to 7 days
reduced acquisitions by 28%. It is also striking that by switching to an antibiotic agent with a
lower impact (antibiotic type B) acquisitions were reduced by 75% and 48%, for prevalence of
1% and 10% carriage on admission, respectively (scenario II).
Our results are based on a hospital with characteristics as specified in Table 1. In order to
examine how variation in hospital characteristics impacts the ARB-H acquisition rate, we con-
ducted a sensitivity analysis for the nurse-patient ratio, nurses’ compliance with infection con-
trol measures, and number of patients per ward (S1 Fig). Nurses’ compliance has the strongest
impact on the rate of ARB-H acquisition: reducing compliance from 50% to 40% more than
triples acquisitions, while increasing compliance from 50% to 60% reduces acquisitions by
more than half. Reducing the number of patients per ward from 40 to 8 decreases ARB-H
acquisitions by 15% -20%. Varying the nurse-patient ratio does not significantly impact the
acquisition rate. In all these scenarios, the relative impact of increased antibiotic density on the
ARB-H acquisition rate remains similar.
Discussion
Transmission is the main driver for the spread of most ARB. Controlled experiments to study
the effect of antibiotic interventions to reduce transmission of ARB at the hospital level are dif-
ficult to perform because of the need to control all potential confounders. This is especially
challenging because antibiotic interventions are often implemented as part of a bundle of
infection control measures that affect ARB transmission [49].
Therefore, we used ABM to understand the effect of antibiotics on the transmission dynam-
ics and the potential of stewardship interventions. We demonstrated that an increase in antibi-
otic use increases the incidence of ARB acquisition. At the individual level, the patient’s risk
Fig 4. The effect of various antibiotic stewardship interventions on the daily number of ARB-H acquisitions. Prevalence of colonization among admitted
patients is 1% and 10%. The note above each bar describes a scenario; % refers to the proportion of admitted patients treated with antibiotics; type is the antibiotic
agent, where the characteristics of antibiotic type A are C = 4, V = 4 and of antibiotic type B are C = 2 and V = 2; days refer to duration of treatment. Percentage
inside the bar indicates reduction in acquisition relative to the reference scenario.
https://doi.org/10.1371/journal.pone.0197111.g004
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increases in parallel with antibiotic density, not only for patients treated with antibiotics but
also for those not treated. These effects translate into an exponential increase in incidence of
ARB acquisitions when antibiotic density increases and when the antibiotic agent has a high
affect.
We found that characteristics of the antibiotic agent used, i.e., its effect on contagiousness
and vulnerability, are crucial in determining the antibiotic’s impact on the spread of resistance.
Our models showed that choosing an agent with a favorable profile in terms of V and C is an
important antibiotic stewardship intervention. Yet, in the real world these effects are under-
studied and the values of V and C for different antibiotic agents are mostly unknown. More-
over, it is very likely that each antibiotic agent has different effects for different ARB. Methods
to measure the effects of C and V of antibiotics should be developed and standardized and
should be incorporated into drug development programs and drug approval packages.
Our simulations revealed that antibiotic density affects ARB transmission more consider-
ably in the early stages of antibiotic resistance spread, when prevalence among admitted
patients is low. Antibiotics have a greater impact on the incidence of ARB acquisition when
the ARB strain is highly transmissible. Since highly transmissible strains pose a greater risk to
become widespread, antibiotic stewardship interventions can be a powerful tool to combat
their spread. We found that reducing antibiotic density has a greater impact on the incidence
of ARB acquisition in settings of high antibiotic use. This is an important finding, as variability
in antibiotic use between similar wards suggests that reduction in antibiotic density can be
achieved in high use settings; such reductions will result in a highly beneficial effect on acquisi-
tion of ARB.
Antibiotic use can be viewed as "tragedy of the commons" where individuals, for their own
good, exploit a shared limited resource, eventually leading to its depletion [50, 51]. Antibiotic
treatment is sometimes portrayed as beneficial at the individual patient level and harmful at
the population level [52]. In contrast to this belief, our simulations reveal that the risk of ARB
acquisition for a patient treated with antibiotic is substantial in high antibiotic density environ-
ments. Clinicians need to recognize this risk when considering antibiotic therapy for their
patients in view of the fact that studies suggest that colonization will progress to clinical infec-
tion in 8%- 30% of patients colonized by ARB [53–55].
Our study has several limitations. First, we did not take into account the effect of antibiotics
on de novo emergence of resistance. Second, for simplicity in our scenarios, all antibiotics used
in the hospital have uniform characteristics. In the real world a mixture of agents are used
simultaneously. This should not change the conclusions derived from our results but will
make translation into the hospital setting more complex. Third, we modeled a typical hospital
with certain transmission and infection control characteristics. The sensitivity analysis we con-
ducted indicates that the level of staff member compliance with infection control has a signifi-
cant impact on the rate of acquisitions but the relative effects of antibiotics on the spread of
ARB are consistent.
In conclusion, our simulations demonstrate that antibiotic treatment in the hospital setting
plays an important role in determining the spread of resistance. It shows that interventions to
limit antibiotic use have the potential to rapidly reduce the spread of resistance, and that the
risk to the individual patient treated with antibiotics of acquiring antibiotic-resistant bacteria
is substantial.
Supporting information
S1 Fig. Sensitivity analysis of the impact of antibiotic density on acquisition of ARB under
various hospital characteristics. ARB acquisitions per 100,000 patient days (PD) as antibiotic
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density increases. (A) The level of nurses’ compliance with infection control is: 40%, 50% and
60%; (B) Number of patients per ward is: 8, 16 and 40; (C) Nurse-patient ratio is: 1:8, 1:4, 1:2.
In all simulations the resistant bacteria is ARB-H, the characteristics of the antibiotic agent are
V = 2 and C = 2, and prevalence of colonization among admitted patients is 1%.
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